New Delhi, 15 Apr, (CXO Media): Novo Nordisk has partnered with OpenAI to deploy artificial intelligence across its drug research and manufacturing operations.
The company plans to integrate OpenAI’s AI tools across its research, manufacturing, and commercial functions. AI In Drug Discovery efforts will focus on analysing large scientific datasets to identify potential drug candidates and reduce the time required to move from research to clinical development. Pilot programmes will begin across key divisions, with wider adoption targeted by the end of 2026. The work will prioritise therapies for chronic diseases such as diabetes and obesity, where treatment demand continues to rise.
Operational Integration And Workforce Readiness will also form part of the collaboration. Novo Nordisk aims to use AI to improve production planning, supply chain processes, and internal operations. The partnership includes training initiatives to improve AI-related skills among employees and support technology adoption across teams.
The company stated that the rollout will follow defined Data Governance And Compliance standards, including safeguards for data security and human oversight. The move reflects broader adoption of artificial intelligence across pharmaceutical research, where companies are investing in digital tools to streamline development cycles and improve operational efficiency.
